Compare iShares Bitcoin Trust (IBIT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Bitcoin Trust trades at $36.11, while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| IBIT | VRTX | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $71.29 | $529.65 |
52-Week Low | $33.29 | $376.62 |
Market Cap | — | $132.79B |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $36.80, up 0.85% today, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $36 and resistance at $37. Recent news highlights strong institutional interest, with BlackRock's head of digital assets noting 'overwhelming demand' for crypto ETFs (Bloomberg, 2026-08-10).
The outlook is cautiously optimistic given technical strength and institutional inflows, but risks include Bitcoin price volatility and regulatory uncertainty. Analyst sentiment is mixed, with some recommending long-term buys amid crypto market downturns.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
